KRAS and neoplasm: A molecular testing panel of the tumor tissue showed the presence of 21 mutations (none of them treatable), including MDM2 (murine double minute 2), KRAS (Kirsten rat sarcoma) amplification, RB1 (retinoblastoma protein) amplification, and STK11 (serine/threonine kinase 11).